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Abstract
Background: The Patient-Oriented Eczema Measure (POEM) has been recom-
mended as the core patient-reported outcome measure for trials of eczema treat-
ments. Using data from the Choice of Moisturiser for Eczema Treatment
randomized feasibility study, we assess the responsiveness to change and deter-
mine the minimal clinically important difference (MCID) of the POEM in young
children with eczema.
Methods: Responsiveness to change by repeated administrations of the POEM
was investigated in relation to change recalled using the Parent Global Assess-
ment (PGA) measure. Five methods of determining the MCID of the POEM
were employed; three anchor-based methods using PGA as the anchor: the
within-patient score change, between-patient score change and sensitivity and
specificity method, and two distribution-based methods: effect size estimate and
the one half standard deviation of the baseline distribution of POEM scores.
Results: Successive POEM scores were found to be responsive to change in eczema
severity. The MCID of the POEM change score, in relation to a slight improvement
in eczema severity as recalled by parents on the PGA, estimated by the within-
patient score change (4.27), the between-patient score change (2.89) and the sensi-
tivity and specificity method (3.00) was similar to the one half standard deviation of
the POEM baseline scores (2.94) and the effect size estimate (2.50).
Conclusions: The Patient-Oriented Eczema Measure as applied to young children
is responsive to change, and the MCID is around 3. This study will encourage
the use of POEM and aid in determining sample size for future randomized con-
trolled trials of treatments for eczema in young children.
Background
Eczema is the most common inflammatory skin disorder in
childhood (1, 2). However, there is a lack of randomized con-
trolled trial (RCT) evidence for many of the commonly used
treatments, such as emollients. Crucial to the design of RCTs
is the choice of outcome measures which should cover the
spectrum of effects important to clinicians and patients and
should be a valid measure and responsive to change in
eczema severity. Furthermore, it is difficult to interpret the
body of evidence from research that has been carried out
because of the variety of different outcome measures that
have been used. The Harmonising Outcome Measures for
Eczema (HOME) initiative (3, 4) has recommended that
Eczema Area and Severity Index (EASI) (5, 6) and, more
recently, the Patient-Oriented Eczema Measure (POEM) (7)
are included as core clinical and patient-reported outcome
measures, respectively, in clinical eczema trials.
However, there are limited studies determining the minimal
clinically important difference (MCID, the smallest change in
an outcome score that is important to clinicians and or care-
givers) of these measures, especially in populations of chil-
dren with mild-to-moderate eczema, hindering the planning
and design of trials. The number of participants in trials
(sample size) is determined on the basis of probability
(power) to detect a true clinically important difference in the
Allergy 71 (2016) 1620–1625 © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd1620
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Allergy
chosen primary outcome. In securing funding and to support
the design and delivery of trials of eczema treatments, it is
important to be able to bring together a coherent summary
of the existing evidence and to justify the choice of outcome
measures and present a convincing research plan.
To address these issues using data from the Choice of
Moisturiser for Eczema Treatment (COMET) randomized
feasibility study (8), we assess the responsiveness to change
and determine the MCID of POEM according to parents
with the use of the Parent Global Assessment (PGA).
Participants, data and outcome measures
COMET (8) was a randomized feasibility study designed to
determine the feasibility of recruiting young children (from
1 month to <5 years of age) with eczema from primary care
within the UK. Details of the study are published elsewhere
(Ridd et al., under submission BMJ Open), but in summary,
197 participating children were randomized to one of four
commonly prescribed emollients and followed up for
3 months. Parent-completed diaries of outcome measures
were collected which included the weekly POEM (Box 1) and
monthly PGA measures.
The POEM measure (7) comprises seven questions each
asking the parent about their experience of their child’s eczema
in the last week. Each question is rated on a five-point scale
from either no days (scoring 0) to every day (scoring 4). The
seven question’s scores are added together to create a total
POEM score with a minimum score of 0 and a maximum of
28, where a lower score is a better outcome. If one question is
unanswered, it is scored as 0 and a total score is still calculated;
however, if more than one question is missing, then a total
score is not calculated and it is assumed to be missing.
The Parent Global Assessment asks ‘How is your child’s
eczema compared with one month ago?’ with a response of
‘Much better’ (score of 2), ‘Better’ (score of 1), ‘No difference’
(score of 0), ‘Worse’ (score of -1) or ‘Much worse’ (score of
-2). Therefore, the PGA is a measure of change in eczema
severity where a higher score represents an improvement.
Analysis
The POEM outcome measure was compared with the PGA
because it is a simple yet meaningful external anchor. The
responsiveness of the POEM to change was compared with
the PGA at each month by presenting global responsiveness
curves of mean change scores over time (9). As the POEM
was asked weekly, the month’s score was taken as the final
week’s score, that is month 1 is week 4, month 2 is week 8
and month 3 is week 12. Change over a month on the
POEM measure was defined as the previous month’s score
minus the current month’s score (e.g. week 0‐week 4), which
was compared with the corresponding monthly PGA score.
The POEM outcome measure defines a lower score as a
better outcome; therefore, a positive change score (as defined
here) is an improvement over time. The PGA score repre-
sents a change in eczema severity over one month, and a
higher score represents a better outcome.
We employed five methods aimed at determining the
MCID for the POEM measure. The three anchor-based
approaches used were the within-patient score change
method, between-patient score change method and the sensi-
tivity and specificity method. All anchor-based methods
require an ‘anchor’ measure and use subgroups defined by
the scores of this anchor measure to determine the MICD. In
our study, the ‘anchor’ measure is the PGA.
The within-patient score change method used the mean
change in POEM scores of those classified as being in mini-
mal-change subgroup of the PGA. We defined the minimal-
change subgroup as those parents that report their child (the
participant) being ‘better’ than the previous month (10). It
has been suggested that the minimal-change subgroup should
also include those that report their child becoming ‘worse’ on
the PGA compared with the previous month (11). However,
to combine the POEM scores of these two subgroups, an
assumption must be made that the distribution of POEM
change scores is identical except for the sign. This assump-
tion can be tested using a Mann–Whitney U-test [Wilcoxen
rank-sum (12)] for two independent samples on the absolute
values (disregarding the sign) of the POEM change scores.
Revicki et al. (11) suggest that definition of the within-
patient score change MCID should be those within the small-
est improvement group, those who respond ‘better’ to the
PGA, as long as those participants have larger changes in
outcome score than the stable ‘no difference’ group.
The between-patient score change method used the differ-
ence in the mean POEM change scores of two adjacent sub-
groups of the PGA (13). The two subgroups selected were
Box 1: Patient-Oriented Eczema Measure (POEM)
Over the last week . . .
1) . . . on how many days has your child’s skin been itchy
because of their eczema?
2) . . . on how many nights has your child’s sleep been dis-
turbed because of their eczema?
3) . . . on how many days has your child’s skin been bleeding
because of their eczema?
4) . . . on how many days has your child’s skin been weeping
or oozing clear fluid because of their eczema?
5) . . . on how many days has your child’s skin been cracked
because of their eczema?
6) . . . on how many days has your child’s skin been flaking
off because of their eczema?
7) . . . on how many days has your child’s skin felt dry or
rough because of their eczema?
Reponses:
• No days (score of 0)
• 1–2 days (score of 1)
• 3–4 days (score of 2)
• 5–6 days (score of 3)
• Every day (score of 4)
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those parents that responded that their child was ‘better’, or
there was ‘no difference’ in their eczema compared with
one month ago.
The sensitivity- and specificity-based method selects the
MCID which most optimally discriminates between groups
of participants classified using their response to the PGA.
The area under the curve (AUC) of the receiver operating
characteristic (ROC) curve was used to identify the cut-off
score of the POEM which represent the greatest correct clas-
sification between those with a PGA response of ‘better’, and
‘no difference’. The MCID is defined as the POEM score
which maximizes Youden’s J statistic (14), defined as sensitiv-
ity-(1-specificity).
Two distribution-based approaches were also used to
determine the MCID of the POEM measure. The effect size
(ES) estimate is a standardized measure of change defined
as the change in the outcome measure scores between base-
line and follow-up, divided by the SD of the baseline
scores. It represents the number of standard deviations by
which the scores have changed from baseline to follow-up;
with an ES of 0.2 being considered small, 0.5 moderate and
0.8 large (13, 15, 16). Half of the standard deviation of the
baseline POEM scores was also calculated as this is a met-
ric routinely used when determining sample size for clinical
trials (17).
All of these five methods to determine the MCID were car-
ried out using data from the baseline assessment and the first
follow-up; one month after the baseline assessment. This was
chosen as it was hypothesized that the most visible change in
eczema severity would have been seen one month after treat-
ment was started. The results are reported for all participants
and not separated by treatment allocation, as any treatment
difference in outcome would not confound the analysis pre-
sented here.
Results
The study participants were of mean age 21.7 months at
baseline (SD 12.8, n = 197). The majority were White (85%,
n = 182) and male (57%, n = 197). According to the POEM
thresholds of eczema severity defined by Charman et al. (18),
the distribution of participants baseline eczema severity
showed that 14% had clear or almost clear, 33% mild, 42%
moderate and 11% severe eczema (n = 196). About 3%
(5/196) of the participants scored the lowest, and 1% (1/196)
scored the highest POEM score possible at baseline.
As can be seen from Table 1, the decrease in average
POEM scores suggests an improvement over time. The
numbers analysed decrease because of missing data (raw
POEM scores <1% to 28%, first follow-up PGA 23%,
change in POEM over first follow-up month and PGA at
first follow-up month 25%). However, this attrition is unli-
kely to have altered the relationship between the POEM
and PGA measures and is therefore not likely to have con-
founded the anchor-based estimates of the MCID. However,
this attrition may lead to some underestimation of the dis-
tribution-based MCID estimates if, for example those for
whom treatment is least effective do not respond. No meth-
ods were used to impute the missing data. There is little
evidence of skewness as the means are similar to the median
values. There is evidence of a moderate-to-strong correlation
(Pearson’s correlation coefficients 0.48 to 0.74) between the
parent-reported POEM measure at different time-points.
This shows that children in the study cohort with the most
severe symptoms at baseline are still relatively worse at each
follow-up visit.
Table 1 Summary statistics of Patient-Oriented Eczema Measure (POEM) and Parent Global Assessment (PGA) outcome measure at each
time-point
POEM PGA
Mean (SD)
Median (25th, 75th
percentile)
N responding
(% missing)
Modal
response
Number giving modal
response/number
responding
Baseline 8.80 (5.87) 8.00 (4.00, 12.00) 196 (<1% missing) NA
Month 1 (week 4) 5.73 (5.38) 4.00 (2.00, 8.00) 153 (22% missing) No difference 53/152
Month 2 (week 8) 5.32 (5.81) 3.00 (1.00, 8.00) 144 (27% missing) Better 48/139
Month 3 (week 12) 4.31 (4.67) 3.00 (1.00, 7.00) 142 (28% missing) Better 50/142
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Figure 1 Responsiveness of Patient-Oriented Eczema Measure
outcome measure over time compared with Parent Global Assess-
ment (PGA). Higher positive score indicates greater improvement
on both measures. PGA is an ordered categorical variable, analysed
here as continuous.
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Responsiveness
Figure 1 illustrates the responsiveness of the POEM measure
compared with the PGA measure. It shows the mean change
score of the POEM measure against the mean score of the
PGA at each time-point. As the PGA question asks how the
parents view their child’s eczema compared with one month
ago, the mean scores presented here can be interpreted as a
change in eczema severity.
It can be seen that the POEM appears to respond to
changes in underlying eczema severity as measured by
PGA as the anchor. Both measures show improvement at
each time-point compared with previous; however, the tim-
ing of the biggest improvement differs between the two
measures. The largest change in POEM score is seen
between baseline and month 1 with a mean change of
2.50. There is a marked increase in mean PGA scores
between month 1 and month 2 (representing an improve-
ment in overall eczema severity) mirroring the more modest
improvement in mean POEM change scores during this
period.
The Pearson’s correlation coefficient between the POEM
change score and the PGA at month one is 0.48 which shows
there is modest agreement between the two measures of
change. The children who show the greatest improvement on
POEM also tend to show the greatest improvement on the
PGA score.
Anchor-based approaches of determining the MCID
Within-patient score change
The minimal-change subgroup of the PGA for this method
was those who report their child (the participant) becoming
‘better’ compared with the previous month. The results of
the Mann–Whitney U-test of equality (12) of distributions
of those in the ‘better’ and ‘worse’ subgroups of the PGA
shows that there is strong evidence that these subgroup
samples are from populations with different distributions
(P < 0.001), and therefore, we cannot confidently combine
these two subgroups into the same minimal-change sub-
group.
The mean POEM change score for those participants in
the ‘no difference’ PGA subgroup is 1.38 (Table 2), which is
smaller than the change score in the smallest improvement,
‘better’ subgroup of the PGA, and therefore, the MCID is
4.27 (95% CI 3.32–5.22) (Table 2).
Between-patient score change
The between-patient score change MCID is defined as the
difference in outcome scores of those within two adjacent
groups of the PGA. We calculated this as the difference in
mean POEM change scores of those in the ‘better’ subgroup
and those in the ‘no difference’ subgroup. The MCID using
this definition is 2.89 (95% CI 1.33–4.44, n = 100). Table 2
shows the POEM scores by PGA response at month 1, and
it can be seen that the POEM scores are decreasing as the
PGA response improves.
Sensitivity- and specificity-based approach
Comparing those participants in the ‘better’ and ‘no differ-
ence’ subgroups of the PGA, the AUC of the ROC curve is
acceptable at 0.71 (95% CI 0.61–0.81, n = 100) (13). The
MCID by this method, which can be defined as the POEM
change score which maximizes Youden’s J statistic [sensitiv-
ity-(1-specificity)] (14), is 3 with 0.71 sensitivity and 0.25
false-positive rate (1-specificity) (Fig. 2).
Distribution-based approach of determining the MCID
Effect size and half standard deviation of baseline scores
The ES is calculated by dividing the change in outcome mea-
sure scores from baseline to the first follow-up month by the
SD of the baseline scores; the result is 0.43 (95% CI 0.29–
0.56). The change score equivalent to this ES is the mean
change score of all the participants; the result is 2.50
3
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Figure 2 Receiver operating characteristic curve of within-patient
Patient-Oriented Eczema Measure change scores in classifying
according to Parent Global Assessment subgroups of ‘better’ vs
‘no difference’.
Table 2 Patient-Oriented Eczema Measure (POEM) raw and
change scores by Parent Global Assessment (PGA) response at
month 1
POEM
PGA Mean (SD)* Mean (SD)*
Mean change
score (SD)†
Response
at month 1 Baseline Month 1
Baseline
‐Month 1
Number
analysed
Much worse 19.00 (12.73) 21.00 (8.49) ‐2.00 (4.24) 2
Worse 7.50 (5.58) 7.97 (5.46) ‐0.47 (5.34) 30
No difference 7.90 (5.72) 6.52 (5.44) 1.38 (4.42) 52
Better 8.31 (4.70) 4.04 (3.97) 4.27 (3.27) 48
Much better 9.56 (5.05) 2.81 (3.58) 6.75 (4.55) 16
*A lower POEM score is more positive.
†A positive change score shows improvement over time.
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(n = 153). Half the standard deviation of the baseline POEM
scores is 2.94 (half of baseline SD of 5.87) (Table 1) with
95% CI 2.67–3.26.
Discussion
Summary of findings
This is the first published study of the responsiveness and
MCID of POEM for young children within primary care.
We found that POEM was responsive to change in eczema
severity over the three time-points, shown by comparison
with the PGA measure (Fig. 1) with a trend of a decrease in
overall symptom severity over time. The three different
anchor-based approaches (using the PGA as the anchor) used
to calculate the MCID of POEM all gave different values of
the MCID of a slight improvement in the POEM change
score of either 4.27 (within patient method), 2.89 (between
patient) or 3 (AUC generated from the ROC curve). Whilst
the distribution-based methods use data from the whole
cohort rather than only those experiencing modest change,
all five methods broadly concur with an MCID of 3.
In conclusion, The Patient-Oriented Eczema Measure
(POEM) as applied to young children is responsive to change
and the MCID is around 3. This improvement of 3 points in
the POEM outcome measure could be achieved by a change
on one question (symptom of eczema) equal to a reduction
in number of days the symptom occurred from every day
(score of 4) to 1–2 days (score of 1) or from 5–6 days (score
of 3) to no days (score of 0).
Strengths and weaknesses
This study used the responsiveness, interpretability and gen-
eralizability checklists within the Consensus-based Standards
for the selection of health Measurement INstruments (COS-
MIN) guidelines (19).
The anchor-based methods for calculation of the MCID
have greater face validity as they define the MCID as a con-
trast between those perceived on a global scale as not having
changed and those having improved a modest amount. How-
ever, the five contrasting methods each gave estimates of the
MCID of around 3 for the POEM measure in young chil-
dren.
The children that participated in this study were recruited
from a range of different GP surgeries amongst areas varying
in levels of deprivation (Index of Multiple Deprivation ‘dec-
iles’ 2 to 10), and therefore, we believe that these participants
were representative of young children with eczema within the
UK.
Important criticisms of the methods used are that the dis-
tribution-based approaches are calculated using data from all
participants, and therefore, this result is not easily compara-
ble with the estimates of the MCID from the anchor-based
methods which are based on subgroup(s) of participants
stratified by their response to the PGA, and these results do
not take into account the improvement or decline in eczema
severity as seen by parents.
The PGA scale has not been validated or tested for relia-
bility; parents may struggle to recall their child’s previous
health state at a specified time-point to determine whether
their state has changed. Therefore, global measures of change
are usually more strongly correlated with the current state
compared with the previous state (20). This hypothesis is
supported within these data by the larger absolute Pearson’s
correlation coefficient of 0.4 seen between the raw POEM
score and the PGA at month 1, than that observed between
the raw POEM score at baseline and the PGA at month 1 of
0.03.
These results demonstrate that repeated administrations of
a parent-completed assessment of a child’s eczema symptoms
(POEM) are sensitive to that parent’s recall of change in
symptoms over the same period (PGA). Indeed, for the rea-
sons mentioned above, repeated administrations of POEM
may be more accurate. Furthermore, we have used parent
recall of change to determine the MCID for the POEM.
Our estimate of the MCID is similar to that found by
Schram et al. (9). of 3.4 using results from 80 participants in
two trials (MAcAD and PROVE); however, our results are
based on a larger sample of participants (n = 148). They also
found the POEM to be responsive to change over time com-
pared with their constructed PGA which was not phrased as
a change over time, as in our study, and was scored on a
six-point Likert scale of disease severity. However, these
were trials of adult populations with severe eczema, and
therefore, the results may not be comparable with our study
in young children from the primary care population where
the majority of the participants were classified as suffering
from moderate eczema (42% of 196, baseline POEM classifi-
cation).
Clinical and research implications
The MCID of the POEM score has not previously been
established in young children with eczema; however, it has
been used as an outcome measure and for sample size calcu-
lations of randomized controlled trials without knowing the
magnitude of the effect that it can show (21–23). This study
will therefore help to more accurately determine sample size
calculations for future RCTs looking to use POEM as an
outcome measure and will aid interpretation of differences in
POEM scores.
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